HOME > ORGANIZATION
ORGANIZATION
- SAMURAI Biotech Association Presents Petition to Health Minister Calling for NHI Pricing System Reflecting Economic Assessment
November 25, 2011
- JPMA, FPMAJ Call on LDP Council on Budget and Tax System with Requests for Next Year
November 24, 2011
- JACDS Discusses Problems Expected from Ban on Dispensing Point Services
November 21, 2011
- Plaintiffs Appeal to the Supreme Court: Iressa Appeal Trial
November 18, 2011
- 6 Indian Generics Companies Including Zydus Form Association, to Start Operations This Month
November 18, 2011
- JPMA Postpones Announcement of Views on TPP,“Will Not Comment Based on Speculation”
November 17, 2011
- Plaintiffs Say High Court Ruling over Iressa “Completely Denies Goals in Medical Administration”
November 17, 2011
- Top JPWA Officials Stress Importance of Wholesalers in Urgent Press Conference
November 17, 2011
- NEDO Decides to Provide Assistance to Four Projects to Develop Bio-Pharmaceutical Manufacturing Technology
November 16, 2011
- JPMA Campaign Highlights Value of New Drug Development
November 15, 2011
- Foreign Countries Interested in Japan’s New Promotion of Generics: IGPA Annual Conference
November 14, 2011
- Premium for Development of New Drugs Is Fiscal Neutrality System: Mr Kamoya of JPMA
November 11, 2011
- JPWA's Bessho Says Promotion of Unit-Priced Contracts by Product First and Foremost
November 11, 2011
- Trial of Premium for New Drug Development Should Continue: Dr Suzuki of JMA
November 1, 2011
- Prescription Doubts Found in 3.15% of Prescriptions, 70% of Those Were Changed: JPA Survey
October 28, 2011
- FPMAJ to Request DPJ to Make Premiums Permanent
October 27, 2011
- JPA’s Yamamoto Calls for Deliberation on TPP after Clarification
October 25, 2011
- JMA Openly Opposes TPP; JPA, JDA, JNA Express Concern
October 24, 2011
- FPMAJ Drafting GLs on Radiation Testing for Crude Drugs
October 21, 2011
- JPMA Makes Pamphlets to Promote Understanding of PC
October 20, 2011
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…